Know Cancer

forgot password

A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/Phase 2
18 Years
Open (Enrolling)
Refractory Multiple Myeloma

Thank you

Trial Information

A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma


Phase I: Define the highest tolerated low dose (HTLD) and safety of azacitidine given at low
but increasing doses up to 50mg/m2 twice a week concurrently with standard dose lenalidomide
and low dose dexamethasone in patients with relapsed or refractory multiple myeloma.

Phase II: Response according to international response criteria (>= PR) and clinical benefit
response (>= minor response according to adapted EBMT (European Group for Blood and Marrow
Transplantation) criteria). PR=partial response


- Correlate response with plasma activity of the azacitidine inactivating enzyme cytidine
deaminase (CDA)

- Progression-free survival and overall survival

- Peripheral blood hematopoietic progenitor (CD34+) yield and time to neutrophil and
platelet recovery in patients undergoing autologous stem cell transplantation

- Promoter demethylation and gene reactivation in myeloma cells and hematopoietic
progenitors treated at the HTLD level after cycle 1

- Changes in global gene expression in myeloma cells treated at the HTLD level after
cycle 1


This is a phase I, dose-escalation study of azacitidine followed by a phase II study.

Patients receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once
weekly starting on day 1. Patients also receive oral lenalidomide once daily on days 1-21.
Treatment repeats every 28 days for 6 courses. Patients then continue to receive
lenalidomide as maintenance therapy. Treatment continues in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 3 years.

Inclusion Criteria


- Understand and voluntarily sign an informed consent form

- Age ≥18 years at the time of signing the informed consent form

- Able to adhere to the study visit schedule and other protocol requirements

- Refractory or relapsed multiple myeloma

- Measurable disease defined as at least one of the following: Serum m-spike >= 1g/dL,
urine m-spike >= 200mg/24hrs, serum free light chains >= 100mg/L (provided the
kappa/lambda ratio is abnormal), or bone marrow plasma cells >= 30%

- Previous therapy with IMiD™ compounds (thalidomide, lenalidomide, pomalidomide),
proteasome inhibitors (bortezomib, carfilzomib), and corticosteroids must be
discontinued at least 14 days before entry onto this study.

- Previous cytotoxic chemotherapy (e.g. alkylating chemotherapy, anthracyclines, and
vinca alkaloids), radiation therapy to the pelvis, and any experimental therapy other
than carfilzomib or pomalidomide must have been discontinued at least 28 days prior
to entry onto this study.

- ECOG performance status of ≤ 2 at study entry (see Appendix II).

- Laboratory test results within these ranges:

- Absolute neutrophil count ≥ 1,500 /mm³

- Platelet count ≥ 75,000/mm³

- Calculated creatinine clearance (Cockroft-Gault) ≥ 30ml/min.

- Total bilirubin ≤ 1.5 x ULN

- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase
[AST]) and serum glutamic-pyruvic transaminase (SGPT) (alanine
aminotransferase [ALT]) levels ≤2 x ULN

- Disease-free of prior malignancies for ≥ 5 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
or breast.

- All study participants must be registered into the mandatory RevAssist® program, and
be willing and able to comply with the requirements of RevAssist®.

- Females of childbearing potential (FCBP)must have a negative serum or urine pregnancy
test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again
within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7
days) and must either commit to continued abstinence from heterosexual intercourse or
begin TWO acceptable methods of birth control, one highly effective method and one
additional effective method AT THE SAME TIME, at least 28 days before she starts
taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must
agree to use a latex condom during sexual contact with a FCBP even if they have had a
successful vasectomy. See Appendix: Risks of Fetal Exposure, Pregnancy Testing
Guidelines and Acceptable Birth Control Methods.

- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
intolerant to ASA may use warfarin or low molecular weight heparin) if no additional
risk factor for VTE other than myeloma diagnosis according to IMW guidelines

- Able to take low molecular weight heparin or warfarin if >1 additional risk factor
for VTE according to IMW guidelines


- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form

- Pregnant or breast feeding females (Lactating females must agree not to breast feed
while taking lenalidomide or azacitidine)

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study

- Use of any experimental drug or therapy other than carfilzomib and pomalidomide
within 28 days of treatment start on this protocol.

- Neuropathy > Grade 2

- Known hypersensitivity to thalidomide, lenalidomide, azacitidine, or mannitol

- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or lenalidomide drugs

- Concurrent use of other anti-cancer agents or treatments, concurrent radiation to the
pelvis. Palliative radiation to areas outside the pelvis is allowed

- Known positive for HIV or infectious hepatitis, type B or C

- Previous inability to tolerate full-dose lenalidomide, adjusted to creatinine
clearance (CrCl) according to Cockroft-Gault at the time of previous lenalidomide
treatment (25mg day 1-21 every 28 days if CrCl > 60ml/min, 10mg lenalidomide d1-21
every 28 days if CrCl < 60mL/min but > 30mL/min, lenalidomide 15mg every 48 h d1-21
every 28 days if CrCl < 30mL/min but not requiring dialysis, lenalidomide 5mg daily,
day 1-21 every 28 days if CrCl < 30mL/min and requiring dialysis).

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase I: Highest tolerated low dose (HTLD)

Outcome Description:

azacitidine given at low but increasing doses up to 50mg/m2 twice a week

Outcome Time Frame:

during the first 28-day cycle

Safety Issue:


Principal Investigator

Frederic Reu

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

June 2010

Completion Date:

Related Keywords:

  • Refractory Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio  44106-5065
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio  44195